Financial Data and Key Metrics Changes - The company reported net revenues of $28.5 million for Q1 2025, which is a slight decrease on a sequential quarterly basis despite an increase in prescriptions filled [30][21] - The gross to net discount rate improved to 53%, with expectations to range between 55% and 65% for the remainder of 2025 [31][76] - Non-GAAP R&D expenses were $7.9 million, a 4% decrease year-over-year, while non-GAAP SG&A expenses were $90.3 million, a 57% increase compared to the same period in 2024 [32] Business Line Data and Key Metrics Changes - Approximately 127,000 filled Vaquesna prescriptions were recorded in Q1 2025, representing an 8% growth over Q4 2024 [25] - 75% of prescriptions filled in Q1 were from repeat patients, indicating strong retention [26] - The company has seen a cumulative total of over 390,000 prescriptions filled since launch, with a 30% growth over the last eight weeks [24] Market Data and Key Metrics Changes - The company maintains commercial coverage for over 120 million lives, representing more than 80% of the total commercially insured market [28] - The proportion of prescriptions flowing through retail pharmacies changed to approximately 70% from 75% in the previous quarter, indicating a shift towards cash pay options [27] Company Strategy and Development Direction - The company aims to achieve profitable operations by 2026 while managing costs and focusing on growing Vaquesna sales [10][12] - A shift in strategy includes implementing cost-saving initiatives to reduce operating expenses to less than $55 million per quarter by Q4 2025 [12] - The company is prioritizing field sales activities over direct-to-consumer (DTC) advertising due to lower ROI from the latter [50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory exclusivity of Vaquesna, with the FDA's decision on the citizens petition expected in early June [19][88] - The CEO emphasized the importance of maintaining a disciplined approach to spending and the need to adapt to current capital market conditions [10][36] - Management remains optimistic about the product's market potential and the positive feedback from both patients and physicians [23][97] Other Important Information - The company is experiencing a potential future disruption in the supply of Baquesna triple packs but does not anticipate a material impact on revenues [22] - A reduction in force is planned, affecting approximately 6% of total staffing, to streamline operations [14] Q&A Session Summary Question: Can you provide more color on the timing of the C-suite changes and their impact on the citizens petition process? - Management confirmed that there will be no interruption in the citizens petition activities, and the key team members will continue to engage with the FDA [40][41] Question: Are you speaking to the same individuals at the FDA as before? - There is some continuity in the FDA staff, but senior policy decisions have changed with the new administration [52] Question: How should investors think about the potential impact on overall script growth from the discontinuation of DTC TV spend? - Management indicated that the field sales activities are the primary drivers of growth, and the discontinuation of DTC spending is not expected to adversely impact revenue ramp [58][60] Question: What is the level of conviction regarding the citizens petition response timing? - Management expressed cautious optimism but acknowledged the potential for delays due to FDA turnover [88] Question: Are there still plans to continue pediatric studies? - The EOE study has been deferred pending the citizens petition decision, but other paths for pediatric extension are being evaluated [90]

Core Insights - Phathom Pharmaceuticals is set to present real-world data on its first-in-class treatment VOQUEZNA (vonoprazan) for gastroesophageal reflux disease (GERD) at Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA [1][3] - VOQUEZNA is the only treatment approved by the U.S. FDA for adults for heartburn relief associated with Non-Erosive GERD and for treating all severities of Erosive Esophagitis (Erosive GERD) [1][34] - The data presented will analyze treatment patterns and patient characteristics, indicating VOQUEZNA's potential role for patients inadequately managed by existing therapies [3] Company Activities - Two Phathom-sponsored posters will be presented on May 5, 2025, at the conference, along with a Product Theater highlighting VOQUEZNA [2] - The company will maintain a strong presence at the conference with a booth (1743) on the exhibit floor [2] Industry Context - GERD affects approximately 1 in 5 U.S. adults, with around 70% of the GERD population suffering from Non-Erosive GERD [31][32] - Erosive GERD, affecting about 30% of the GERD population, can lead to severe complications if inadequately treated [33] - The conference will showcase over 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology [8]

Financial Data and Key Metrics Changes - For Q4 2024, the company reported net revenues of $29.7 million, representing an 81% sequential increase [54] - Full year 2024 net revenues totaled $55.3 million, with strong revenue growth observed in each quarter [55] - Gross profit for Q4 2024 was $25.8 million, resulting in a gross margin of 87%, an increase of 155 basis points from Q3 [57] - The company reported a GAAP net loss of $74.5 million for Q4 2024, compared to a loss of $79.6 million in Q4 2023 [62] - Cash and cash equivalents as of December 31, 2024, were $297 million, with an additional $100 million available from a debt facility [63] Business Line Data and Key Metrics Changes - VOQUEZNA prescriptions surpassed 300,000, with approximately 118,000 fills in Q4 2024, reflecting over 70% growth compared to Q3 [32][33] - The refill rate for VOQUEZNA in Q4 was about 70%, indicating strong patient retention [35] - The number of physicians writing prescriptions increased to over 20,000, with 75% of them having written more than one prescription [39][40] Market Data and Key Metrics Changes - VOQUEZNA remains covered for over 120 million lives, with commercial coverage above 80% [44] - The company has secured access for the majority of covered lives with a single step through a generic PPI prescription [45] Company Strategy and Development Direction - The company aims to make VOQUEZNA a household name through increased investment in consumer campaigns and targeting primary care physicians [12][41] - Plans to initiate a Phase 2 trial for eosinophilic esophagitis (EoE) are underway, with the belief that VOQUEZNA can serve as a first-line therapy [15][19] - The company is exploring the development of an orally disintegrating tablet (ODT) formulation to enhance patient compliance [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing launch and development goals for VOQUEZNA, anticipating continued momentum in 2025 [10][11] - The company is prepared for potential challenges in Q1 due to typical seasonal slowness but expects growth to resume thereafter [33][65] - Management emphasized the importance of commercial execution and the potential to displace PPIs in the GERD market [70] Other Important Information - The company submitted a Citizen Petition to the FDA for a 10-year exclusivity period for VOQUEZNA products, with a response expected by June 2025 [23][24] - The company is actively monitoring the OTC market opportunity and exploring real-world data related to GERD symptoms among GLP-1 users [22] Q&A Session Summary Question: Timeline for the Citizen Petition and potential outcomes - Management confirmed the FDA is required to respond within 180 days and expressed confidence in their legal position if the decision is unfavorable [76][78] Question: Expectations for Q1 growth - Management indicated that Q1 is expected to be softer than Q4 due to industry dynamics but anticipates growth to resume later in the quarter [79] Question: Phase 3 trial decision timeline - Management expects to have enough data to make a go/no-go decision by midyear [82] Question: Impact of DTC campaigns on prescribing - Management noted a significant increase in physician requests for VOQUEZNA due to DTC campaigns, with a 55% increase in requests reported [88] Question: Early refill trends for NERD - Management indicated that refill rates are tracking well and are in line with expectations for chronic medications [95] Question: Importance of BlinkRx - Management confirmed that BlinkRx remains important for supporting patient access and increasing refill rates [108] Question: ODT formulation and IP strategy - Management clarified that the ODT formulation and pediatric extension will be developed in parallel [114] Question: Resistance from prescribers - Management reported no significant resistance from prescribers, who are welcoming VOQUEZNA's novel mechanism [123]

Financial Data and Key Metrics Changes - For Q4 2024, the company reported net revenues of $29.7 million, representing an 81% sequential increase quarter-over-quarter [40] - For the full year 2024, net revenues totaled $55.3 million, with strong revenue growth observed in each quarter [40] - Gross profit for Q4 2024 was $25.8 million, equating to a gross margin of 87%, an increase of 155 basis points over Q3 [41] - The company reported a GAAP net loss of $74.5 million for Q4 2024, compared to a loss of $79.6 million in Q4 2023 [46] Business Line Data and Key Metrics Changes - The company has filled over 300,000 prescriptions for its product, with approximately 118,000 filled in Q4 2024, reflecting over 70% growth compared to Q3 [24] - The refill rate among patients continuing therapy was about 70%, indicating strong patient retention [26] - The number of physicians writing prescriptions increased to over 20,000, with 75% of these writers prescribing more than once [28] Market Data and Key Metrics Changes - The company secured commercial coverage for over 120 million lives, with access typically requiring only one generic prescription step [32] - The awareness of the product among primary care physicians has nearly doubled since the product launch [30] - The company anticipates a soft Q1 due to typical seasonal trends but expects growth to resume thereafter [58] Company Strategy and Development Direction - The company plans to enhance brand awareness through a new consumer campaign and increase focus on primary care physicians [11][38] - The company is exploring new indications for its product, including a Phase II trial for eosinophilic esophagitis [12][44] - The company aims to position its product as a first-line therapy alternative to PPIs, leveraging its unique profile [14][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the product's potential to reach blockbuster status and emphasized the importance of commercial execution [9][51] - The company is optimistic about the ongoing launch and development goals, with a focus on driving growth in 2025 [10][21] - Management acknowledged the challenges of the current operating environment but remains committed to leveraging their strong foundation for future success [48] Other Important Information - The company submitted a citizen petition to the FDA for a ten-year exclusivity period for its products, with a response expected by June 2025 [20][56] - The company has a strong patent position, with expectations for extensions under the Hatch-Waxman Act [20] Q&A Session Summary Question: Can you clarify the timeline for the citizen petition and what happens if the decision is unfavorable? - Management confirmed the FDA is required to respond within 180 days and expressed confidence in their legal position if the outcome is not favorable [55][56] Question: What are the expectations for Q1 growth relative to Q4? - Management indicated that Q1 is expected to be softer than Q4 due to industry dynamics but anticipates growth to resume after the initial months [58] Question: When will there be enough data for the Phase III on-demand trial decision? - Management expects to have enough information by mid-year to make a decision regarding the trial [62] Question: Is the DTC campaign driving the increase in prescribing physicians? - Management confirmed that the DTC campaign is effectively motivating patients to request prescriptions, contributing to the increase in prescribers [66] Question: What are the refill trends and usage metrics for the product? - Management reported that refill rates are consistent with expectations and are tracking similarly to PPIs, indicating strong patient adherence [73] Question: How important is the BlinkRx program now that coverage has improved? - Management emphasized that BlinkRx remains important for supporting patients and increasing refill rates [82]

Summary of Phathom Pharmaceuticals (PHAT) Conference Call - February 06, 2025 Company Overview - **Company Name**: Phathom Pharmaceuticals (PHAT) - **Established**: May 2019 - **Key Product**: Venoprazan, licensed from Takeda, launched in late 2023 - **Indications**: Approved for H. Pylori in combination with antibiotics, GERD (gastroesophageal reflux disease) in both erosive and non-erosive forms [3][4] Core Points and Arguments Product Performance and Market Position - Venoprazan has shown superiority over traditional PPIs (Proton Pump Inhibitors) in clinical trials, leading to a positive commercial trajectory [4][5] - The company has achieved over 80% commercial coverage, indicating strong market acceptance despite initial skepticism regarding physician adoption and payer coverage [13][34] - The launch has been successful, with approximately 6,000 prescriptions per week, and expectations for significant growth in 2025 [15][16] Future Plans and Studies - Phathom is pursuing life cycle management for Venoprazan, including studies for eosinophilic esophagitis (EOE), with plans to start Phase II trials in the first half of 2025 [6][10] - The Phase II study will focus on symptom improvement and resolution of fibrotic effects in the esophagus, with results expected in about two years [9][10] - The company is also exploring the potential for an over-the-counter (OTC) version of Venoprazan, which would require long-term safety data and additional studies [73][76] Regulatory and Exclusivity Issues - Phathom is currently addressing an exclusivity issue with the FDA regarding the application of GAIN exclusivity to multiple indications of Venoprazan [5][46] - The company has received patent protection until February 1930 and is pursuing regulatory exclusivity that could extend this to February 1932 [46][50] - A citizen petition has been filed to expedite the FDA's decision on the exclusivity issue, with an expected response by mid-2025 [55][56] Additional Important Insights - The company has a robust commercial team of 320 sales representatives targeting high-volume prescribers, with no plans for expansion in 2025 [39][40] - The refill rates for Venoprazan are tracking similarly to those of traditional PPIs, indicating strong patient retention [27][28] - The market for H. Pylori treatment is limited, with under 1 million patients treated annually, but Phathom is actively engaging prescribers in this area [44][45] Conclusion Phathom Pharmaceuticals is positioned for growth with its innovative product Venoprazan, backed by strong clinical data and a solid commercial strategy. The company is actively addressing regulatory challenges while exploring new market opportunities, including EOE and OTC formulations. The upcoming years are critical for the company's trajectory, particularly in resolving exclusivity issues and expanding its market presence.